Clinical Trials
6 trialsNCT04624633 2026-02-25
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04783415 2024-12-02
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04508647 2024-03-21
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
University of Colorado, Denver
Phase 2 Completed
NCT04692155 2023-09-28
CHOP U2
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02276963 2019-06-06
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Johns Hopkins University
Phase 1 Completed